Label: PREGNYL- choriogonadotropin alfa   

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 12/13

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta, is composed of an alpha and a beta subunit. The alpha sub-unit is essentially identical to the alpha subunits of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha subunit of human thyroid-stimulating hormone (TSH). The beta subunits of these hormones differ in amino acid sequence.

    PREGNYL® (chorionic gonadotropin for injection USP) is a highly purified pyrogen-free preparation obtained from the urine of pregnant females. It is standardized by a biological assay procedure. It is available for intramuscular injection in multiple dose vials containing 10,000 USP units of sterile dried powder with 5 mg monobasic sodium phosphate and 4.4 mg dibasic sodium phosphate. If required, pH is adjusted with sodium hydroxide and/or phosphoric acid. Each package also contains a 10-mL vial of solvent containing: water for injection with 0.56% sodium chloride and 0.9% BENZYL ALCOHOL, WHICH IS NOT FOR USE IN NEWBORNS. If required, pH is adjusted with sodium hydroxide and/or hydrochloric acid.

    Close
  • CLINICAL PHARMACOLOGY

    The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone.

    Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present. This descent is usually reversible when HCG is discontinued.

    During the normal menstrual cycle, LH participates with FSH in the development and maturation of the normal ovarian follicle, and the mid-cycle LH surge triggers ovulation. HCG can substitute for LH in this function. During a normal pregnancy, HCG secreted by the placenta maintains the corpus luteum after LH secretion decreases, supporting continued secretion of estrogen and progesterone and preventing menstruation. HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION.

    Close
  • INDICATIONS AND USAGE

    HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR "NORMAL" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS.

    1. Prepubertal cryptorchidism not due to anatomical obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9.
    2. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.
    3. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.
    Close
  • CONTRAINDICATIONS

    Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG.

    Close
  • WARNINGS

    HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for menotropins.

    Anaphylaxis has been reported with urinary-derived HCG products.

    The principal serious adverse reactions during this use are:
    (1) ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion, (2) rupture of ovarian cysts with resultant hemoperitoneum, (3) multiple births, and (4) arterial thromboembolism.

    Close
  • PRECAUTIONS

    General

    Since androgens may cause fluid retention, HCG should be used with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.

    Pediatric Use

    Induction of androgen secretion by HCG may induce precocious puberty in pediatric patients treated for cryptorchidism. Therapy should be discontinued if signs of precocious puberty occur.

    Geriatric Use

    Clinical studies of PREGNYL® (chorionic gonadotropin for injection USP) did not include subjects aged 65 and over.

    Close
  • ADVERSE REACTIONS

    Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection.

    Hypersensitivity reactions, both localized and systemic in nature, have been reported.

    Close
  • DOSAGE AND ADMINISTRATION

    For intramuscular use only. The dosage regimen employed in any particular case will depend upon the indication for the use, the age and weight of the patient, and the physician's preference. The following regimens have been advocated by various authorities:

    Prepubertal cryptorchidism not due to anatomical obstruction. Therapy is usually instituted in children between the ages of 4 and 9.

    1. 4000 USP units 3 times weekly for 3 weeks.
    2. 5000 USP units every second day for 4 injections.
    3. 15 injections for 500 to 1000 USP units over a period of 6 weeks.
    4. 500 USP units 3 times weekly for 4 to 6 weeks. If this course of treatment is not successful, another series is begun 1 month later, giving 1000 USP units per injection.

    Selected cases of hypogonadotropic hypogonadism in males.

    1. 500 to 1000 USP units 3 times a week for 3 weeks, followed by the same dose twice a week for 3 weeks.
    2. 4000 USP units 3 times weekly for 6 to 9 months, following which the dosage may be reduced to 2000 USP units 3 times weekly for an additional 3 months.

    Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins.

    (See prescribing information for menotropins for dosage and administration for that drug product.)

    5000 to 10,000 USP units 1 day following the last dose of menotropins. (A dosage of 10,000 USP units is recommended in the labeling for menotropins.)

    Directions for Reconstitution

    Two-vial package: Withdraw sterile air from lyophilized vial and inject into diluent vial. Remove 1–10 mL from diluent and add to lyophilized vial; agitate gently until powder is completely dissolved in solution.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    IMPORTANT: USE COMPLETELY AFTER RECONSTITUTION. RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED.

    Close
  • HOW SUPPLIED

    Two-vial package containing:

    1-10 mL lyophilized multiple dose vial containing: 10,000 USP units chorionic gonadotropin per vial, NDC 0052-0315-10.

    1-10 mL vial of solvent containing: water for injection with sodium chloride 0.56% and benzyl alcohol 0.9%, NDC 0052-0325-10.

    When reconstituted, each 10 mL vial contains:

    Chorionic gonadotropin 10,000 USP units
    Monobasic sodium phosphate 5 mg
    Dibasic sodium phosphate 4.4 mg
    Sodium chloride 0.56%
    Benzyl alcohol 0.9%

    If required pH adjusted with sodium hydroxide and/or phosphoric acid.

    Storage

    Store at controlled room temperature 15–30°C (59–86°F). Reconstituted solution is stable for 60 days when refrigerated.

    Close
  • SPL UNCLASSIFIED SECTION

    Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

    Manufactured by: Baxter Pharmaceutical Solutions LLC, Bloomington, IN 47403, USA

    For patent information: www.merck.com/product/patent/home.html

    Copyright © 1976, 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc.
    All rights reserved.

    Revised: 12/2013
    uspi-mk8829-pwi-1312-r006

    Rx only

    Close
  • PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton

    NDC 0052-0315-10

    10-mL multidose vial
    with 10-mL vial of solvent

    Pregnyl®
    (chorionic gonadotropin
    for injection USP)

    10,000
    USP Units/vial

    For Intramuscular
    Injection Only

    Rx only

    PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton
    Close
  • INGREDIENTS AND APPEARANCE
    PREGNYL 
    choriogonadotropin alfa kit
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0052-0315
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0052-0315-10 1 in 1 CARTON
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, MULTI-DOSE 10 mL
    Part 2 1 VIAL 10 mL
    Part 1 of 2
    PREGNYL 
    choriogonadotropin alfa injection, powder, lyophilized, for solution
    Product Information
    Route of Administration INTRAMUSCULAR DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CHORIOGONADOTROPIN ALFA (CHORIOGONADOTROPIN ALFA) CHORIOGONADOTROPIN ALFA 10000 [USP'U]  in 10 mL
    Inactive Ingredients
    Ingredient Name Strength
    SODIUM PHOSPHATE, MONOBASIC  
    SODIUM PHOSPHATE, DIBASIC  
    SODIUM HYDROXIDE  
    PHOSPHORIC ACID  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 10 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA017692 10/20/1976
    Part 2 of 2
    PREGNYL SOLVENT 
    water, sodium chloride and benzyl alcohol injection, solution
    Product Information
    Route of Administration INTRAMUSCULAR DEA Schedule     
    Inactive Ingredients
    Ingredient Name Strength
    WATER  
    SODIUM CHLORIDE  
    BENZYL ALCOHOL  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 10 mL in 1 VIAL
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA017692 10/20/1976
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA017692 10/20/1976
    Labeler - Organon USA Inc. (078796541)
    Establishment
    Name Address ID/FEI Business Operations
    Aspen Oss B.V. 491013870 API MANUFACTURE(0052-0315)
    Establishment
    Name Address ID/FEI Business Operations
    BAXTER PHARMACEUTICAL SOLUTIONS, LLC 604719430 MANUFACTURE(0052-0315)
    Establishment
    Name Address ID/FEI Business Operations
    Aspen Oss B.V. 491017488 API MANUFACTURE(0052-0315)
    Establishment
    Name Address ID/FEI Business Operations
    Merck Sharp & Dohme Corp. 101740835 PACK(0052-0315)
    Close